Ascendia Pharmaceuticals, Inc.

Based in New Jersey, US, and founded in 2012 by Dr. Jingjun “Jim” Huang, Ascendia Pharmaceuticals, Inc. operates as a specialty contract development and manufacturing company that specializes in the invention and development of specialty pharmaceutical products and formulation technologies. Signet Healthcare Partners invested in the company in April 2021.

The firm provides analytical, manufacturing, and formulation services for pre-clinical, clinical-stage drug candidates, and marketed drug products to pharmaceutical companies. The company also offers special development programs such as animal health formulations, ocular formulation development, high potency and drug enforcement administration controlled drug substances, development of complex generics, nano-emulsion and nano-particle formulations, development of 505(b)(2) products, sustained-release by parenteral or oral routes, and peptide formulations. The company's revenue is generated by conducting formulation design and testing for tablet, capsule, parenteral, topical, and lyophilized dosage forms and manufacturing cGMP batches for orally administered dosage forms for both tablets and capsules, as well as by offering a range of equipment needed to address pharmaceutical projects including an isolation hood for working with cytotoxic molecules. Ascendia Pharmaceuticals, Inc.

plans to expand its footprint and manufacturing capacity to continue to meet its growing production needs for the early and late phases of product development.